UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): August 21, 2015

 

CHAMPIONS ONCOLOGY, INC.

 

(Exact name of registrant as specified in its charter)

 

 

Delaware 0-17263 52-1401755           
(State or Other Jurisdiction (Commission File Number) (IRS Employer        
of Incorporation) Identification No.)

 

 

1 University Plaza, Suite 307, Hackensack, New Jersey 07601

(Address of Principal Executive Offices)

 

Registrant’s telephone number, including area code: (410) 369-0365

 

Applicable

(Former Name or Former Address if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

  

INFORMATION TO BE INCLUDED IN THE REPORT

 

 

Item 8.01. Other Events.

 

On August 21, 2015, Champions Oncology, Inc. (the “Company”) issued a press release announcing that its common stock has been approved for listing on The NASDAQ Capital Market.  The Company expects its common stock to begin trading at the opening of trading on August 21, 2015 under the trading symbol “CSBR.”  A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)          Exhibits

 

The following exhibit filed herewith:

 

Exhibit No.

99.1          Press Release dated August 21, 2015

 

 

_____________________________________________________________________________________

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  CHAMPIONS ONCOLOGY, INC.
  (Registrant)
     
     
Date: August 21, 2015 By:           /s/ Joel Ackerman          
    Joel Ackerman
    Chief Executive Officer